Literature DB >> 11645807

We have a prejudice against ourselves -- sentiment, ethics, and reason.

Leo T Rosenberg.   

Abstract

Briefly stated my point is that the well-being of each person in a community conceived abstractly may be all too easily sacrificed for the sake of the abstraction. Physicians may offer critically ill patients places in programs of experimental treatment, but there is commonly a catch to the offer. To take part in a program of clinical experiment a patient must not only risk a possible failure of a fresh drug and the chance of destructive side effects from the drug, but the patients must risk only getting the traditional treatment along with a placebo rather than the experimental drug. Placebo control, double blind critical protocols for testing effects of fresh drugs on critically ill patients are a commonplace. I question the scientific objectivity of the protocols and the underlying ethic, and suggest use of alternate protocols. Experimental tests in the treatment of gram-negative bacteria blood infections, muscular dystrophy, and AIDS and AIDS-related diseases are examples.

Entities:  

Keywords:  Biomedical and Behavioral Research

Mesh:

Substances:

Year:  1993        PMID: 11645807     DOI: 10.1007/bf01138156

Source DB:  PubMed          Journal:  J Med Humanit        ISSN: 1041-3545


  9 in total

1.  A critique of pure reason, a passion to survive: cheating on AIDS trials.

Authors:  Gina Kolata
Journal:  N Y Times Web       Date:  1990-10-21

Review 2.  Plausible structural/functional/behavioral/biochemical transformations following myoblast transfer therapy.

Authors:  P K Law; T G Goodwin; H J Li; M Chen
Journal:  Adv Exp Med Biol       Date:  1990       Impact factor: 2.622

3.  Myoblast transfer improves muscle genetics/structure/function and normalizes the behavior and life-span of dystrophic mice.

Authors:  P K Law; T G Goodwin; H J Li; G Ajamoughli; M Chen
Journal:  Adv Exp Med Biol       Date:  1990       Impact factor: 2.622

4.  Increase in National Hospital Discharge Survey rates for septicemia--United States, 1979-1987.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1990-01-19       Impact factor: 17.586

5.  Dystrophin production induced by myoblast transfer therapy in Duchenne muscular dystrophy.

Authors:  P K Law; T E Bertorini; T G Goodwin; M Chen; Q W Fang; H J Li; D S Kirby; J A Florendo; H G Herrod; G S Golden
Journal:  Lancet       Date:  1990-07-14       Impact factor: 79.321

6.  Low-dose co-trimoxazole for prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus disease.

Authors:  J Ruskin; M LaRiviere
Journal:  Lancet       Date:  1991-02-23       Impact factor: 79.321

7.  The safety and pharmacokinetics of GLQ223 in subjects with AIDS and AIDS-related complex: a phase I study.

Authors:  J O Kahn; L D Kaplan; J G Gambertoglio; D Bredesen; C J Arri; L Turin; T Kibort; R L Williams; J D Lifson; P A Volberding
Journal:  AIDS       Date:  1990-12       Impact factor: 4.177

8.  Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group.

Authors:  E J Ziegler; C J Fisher; C L Sprung; R C Straube; J C Sadoff; G E Foulke; C H Wortel; M P Fink; R P Dellinger; N N Teng
Journal:  N Engl J Med       Date:  1991-02-14       Impact factor: 91.245

9.  A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. The XOMA Sepsis Study Group.

Authors:  R L Greenman; R M Schein; M A Martin; R P Wenzel; N R MacIntyre; G Emmanuel; H Chmel; R B Kohler; M McCarthy; J Plouffe
Journal:  JAMA       Date:  1991-08-28       Impact factor: 56.272

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.